User menu

Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial.

Bibliographic reference Kimura, Go ; Yonese, Junji ; Fukagai, Takashi ; Kamba, Tomomi ; Nishimura, Kazuo ; et. al. Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial.. In: International Journal of Urology, Vol. 23, no.5, p. 395-403 (2016)
Permanent URL http://hdl.handle.net/2078.1/173812
  1. Ferlay J Soerjomataram I Erik M et al GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 2013 http://globocan.iarc.fr
  2. Matsuda A., Matsuda T., Shibata A., Katanoda K., Sobue T., Nishimoto H., , Cancer Incidence and Incidence Rates in Japan in 2007: A Study of 21 Population-based Cancer Registries for the Monitoring of Cancer Incidence in Japan (MCIJ) Project, 10.1093/jjco/hys233
  3. Cancer Information Service Cancer mortality from Vital Statistics in Japan (1958-2014). 2015 http://ganjoho.jp/en/professional/statistics/table_download.html
  4. Xia Shu-Jie, Cui Di, Jiang Qi, An overview of prostate diseases and their characteristics specific to Asian men, 10.1038/aja.2010.137
  5. Huggins, Cancer Res., 1, 293 (1941)
  6. Feldman Brian J., Feldman David, The development of androgen-independent prostate cancer, 10.1038/35094009
  7. Grossmann M. E., Huang H., Tindall D. J., Androgen Receptor Signaling in Androgen-Refractory Prostate Cancer, 10.1093/jnci/93.22.1687
  8. Pienta K. J., Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer, 10.1158/1078-0432.ccr-06-0067
  9. Scher Howard I., Sawyers Charles L., Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis, 10.1200/jco.2005.03.4777
  10. Berthold Dominik R., Pond Gregory R., Soban Freidele, de Wit Ronald, Eisenberger Mario, Tannock Ian F., Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study, 10.1200/jco.2007.12.4008
  11. Seruga Bostjan, Ocana Alberto, Tannock Ian F., Drug resistance in metastatic castration-resistant prostate cancer, 10.1038/nrclinonc.2010.136
  12. Montgomery R. B., Mostaghel E. A., Vessella R., Hess D. L., Kalhorn T. F., Higano C. S., True L. D., Nelson P. S., Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth, 10.1158/0008-5472.can-08-0249
  13. Chen Charlie D, Welsbie Derek S, Tran Chris, Baek Sung Hee, Chen Randy, Vessella Robert, Rosenfeld Michael G, Sawyers Charles L, Molecular determinants of resistance to antiandrogen therapy, 10.1038/nm972
  14. Knudsen K. E., Scher H. I., Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer, 10.1158/1078-0432.ccr-08-2660
  15. Tran C., Ouk S., Clegg N. J., Chen Y., Watson P. A., Arora V., Wongvipat J., Smith-Jones P. M., Yoo D., Kwon A., Wasielewska T., Welsbie D., Chen C. D., Higano C. S., Beer T. M., Hung D. T., Scher H. I., Jung M. E., Sawyers C. L., Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer, 10.1126/science.1168175
  16. Scher Howard I., Fizazi Karim, Saad Fred, Taplin Mary-Ellen, Sternberg Cora N., Miller Kurt, de Wit Ronald, Mulders Peter, Chi Kim N., Shore Neal D., Armstrong Andrew J., Flaig Thomas W., Fléchon Aude, Mainwaring Paul, Fleming Mark, Hainsworth John D., Hirmand Mohammad, Selby Bryan, Seely Lynn, de Bono Johann S., Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy, 10.1056/nejmoa1207506
  17. Beer Tomasz M., Armstrong Andrew J., Rathkopf Dana E., Loriot Yohann, Sternberg Cora N., Higano Celestia S., Iversen Peter, Bhattacharya Suman, Carles Joan, Chowdhury Simon, Davis Ian D., de Bono Johann S., Evans Christopher P., Fizazi Karim, Joshua Anthony M., Kim Choung-Soo, Kimura Go, Mainwaring Paul, Mansbach Harry, Miller Kurt, Noonberg Sarah B., Perabo Frank, Phung De, Saad Fred, Scher Howard I., Taplin Mary-Ellen, Venner Peter M., Tombal Bertrand, Enzalutamide in Metastatic Prostate Cancer before Chemotherapy, 10.1056/nejmoa1405095
  18. Cleeland, Ann. Acad. Med. Singapore, 23, 129 (1994)
  19. Scher Howard I., Halabi Susan, Tannock Ian, Morris Michael, Sternberg Cora N., Carducci Michael A., Eisenberger Mario A., Higano Celestia, Bubley Glenn J., Dreicer Robert, Petrylak Daniel, Kantoff Philip, Basch Ethan, Kelly William Kevin, Figg William D., Small Eric J., Beer Tomasz M., Wilding George, Martin Alison, Hussain Maha, Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group, 10.1200/jco.2007.12.4487
  20. Zhang Ling, Yang Bao-Xue, Zhang Hai-Tao, Wang Jin-Guo, Wang Hong-Liang, Zhao Xue-Jian, Prostate cancer: an emerging threat to the health of aging men in Asia, 10.1038/aja.2010.126
  21. Namiki M., Akaza H., Lee S. E., Song J.-M., Umbas R., Zhou L., Cheok Lee B., Cheng C., Chung M. K., Fukagai T., Hinotsu S., Horie S., Prostate Cancer Working Group Report, 10.1093/jjco/hyq130
  22. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W, Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response., 10.1200/jco.1989.7.5.590
  23. Dorff T. B., Crawford E. D., Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer, 10.1093/annonc/mds216
  24. DeAntoni Edward P., David Crawford E., Oesterling Joseph E., Ross Colleen A., Roy Berger E., McLeod David G., Staggers Frank, Stone Nelson N., Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study, 10.1016/s0090-4295(96)00091-x
  25. Oesterling J.E., Kumamoto Y., Tsukamoto T., Girman C.J., Guess H.A., Masumori N., Jacobsen S.J., Lieber M.M., Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men, 10.1111/j.1464-410x.1995.tb07347.x
  26. Oesterling Joseph E., Serum Prostate-Specific Antigen in a Community-Based Population of Healthy Men : Establishment of Age-Specific Reference Ranges, 10.1001/jama.1993.03510070082041
  27. Chia, Asian Pac. J. Cancer Prev., 8, 375 (2007)
  28. Matsubara N., Uemura H., Satoh T., Suzuki H., Nishiyama T., Uemura H., Hashine K., Imanaka K., Ozono S., Akaza H., A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study), 10.1093/jjco/hyu149
  29. Nozawa Masahiro, Mukai Hirofumi, Takahashi Shunji, Uemura Hiroji, Kosaka Takeo, Onozawa Yusuke, Miyazaki Jun, Suzuki Kazuhiro, Okihara Koji, Arai Yoichi, Kamba Tomomi, Kato Masashi, Nakai Yasutomo, Furuse Hiroshi, Kume Haruki, Ide Hisamitsu, Kitamura Hiroshi, Yokomizo Akira, Kimura Takahiro, Tomita Yoshihiko, Ohno Keiji, Kakehi Yoshiyuki, Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer, 10.1007/s10147-015-0820-9